Ototoxicity

FDA issues orphan drug designation for sodium thiosulfate

Published in Drug Week, April 23rd, 2004

Adherex Technologies, Inc., (AHX) has received orphan drug designation for sodium thiosulfate (STS) from the U.S. Food and Drug Administration (FDA).

The designation was granted for the prevention of platinum-induced ototoxicity in pediatric patients.

"FDA orphan drug designation for STS is a major milestone for both children with cancer and for the company," said William P. Peters, CEO and chairman of Adherex. "Hearing loss among children receiving platinum-based chemotherapy is frequent, permanent and severely disabling and affects nearly a third of all children with cancer. Orphan drug designation for STS makes development commercially viable and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2004-04-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry